Clinical Research on HXZQC
Modern clinical studies have shown that HXZQC has therapeutic effects against viral diseases, such as gastrointestinal-type cold, influenza, upper respiratory infection (URI), and viral enteritis (see  Table 3 ). The Diagnosis and Treatment Scheme of Severe Acute Respiratory Syndrome (SARS) (Version 2004) (Chinese Medical Association and China Association of Chinese Medicine, 2004) recommended that HXZQC could be used for advanced stage pulmonary closure.
Research by Shuping Ma et al. showed that, compared with the control group (Ribavirin, interferon), HXZQC + Western medicines (Ribavirin, interferon) had a significant effect on antidiarrheal time and shortened the total time course in the treatment of children with rotavirus enteritis (p < 0.05) (Ma and Wang, 2012). Xiaoping Han et al. (Han, 2016) randomized 78 influenza patients into control and observation groups. Patients in the control group were given oral oseltamivir phosphate, while patients in the observation group received HXZQC in addition to oseltamivir phosphate. Compared with those in the control group, patients in the observation group had faster relief of fever symptoms, muscle aches, and fatigue (p < 0.05). The total response rate in the observation group was 97.44%, which was higher than the 82.05% of the control group (p < 0.05). The results showed that HXZQC enhanced the efficacy of oseltamivir phosphate in the treatment of influenza. Xingzhou Wu (Wu, 2010) randomized 90 cold dampness patients into two groups: the treatment group received HXZQP, while the control group received Ribavirin injection + Compound paracetamol and amantadine hydrochloride capsules. The total response rate in the treatment group was 88.9% compared to 77.1% in the control group (p < 0.05). Patients in the treatment group exhibited greater improvements in aversion to cold, fever, nasal congestion, running nose, spontaneous sweating, headache, cough and spitting, fatigue and weakness, body ache, and other cold symptoms compared to the control group. Hongjie Zhao et al. studied the efficacy and safety of HXZQC in the treatment of gastrointestinal-type cold by systematic evaluation. A total of 680 patients in eight randomized controlled trials (RCTs) were included in the research, and the results showed that the group receiving HXZQC had a significantly better clinical response than the group using Western medicines alone. The effects of HXZQC were superior to Western medicines in improving single symptoms (such as aversion to cold, fever, bowel sound and diarrhea) (Zhao et al., 2017). Dandan Yu et al. conducted a meta-analysis of 44 studies, including a total of 4,153 patients with acute gastroenteritis. The results showed that treatment with HXZQP + conventional therapy or norfloxacin tablets was superior to a single Western medicine in terms of total response rate and improvement of clinical symptoms (Yu et al., 2019).